JP2006514066A - 置換ヘテロ環化合物 - Google Patents

置換ヘテロ環化合物 Download PDF

Info

Publication number
JP2006514066A
JP2006514066A JP2004566575A JP2004566575A JP2006514066A JP 2006514066 A JP2006514066 A JP 2006514066A JP 2004566575 A JP2004566575 A JP 2004566575A JP 2004566575 A JP2004566575 A JP 2004566575A JP 2006514066 A JP2006514066 A JP 2006514066A
Authority
JP
Japan
Prior art keywords
piperazinyl
optionally substituted
acetamide
compound
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004566575A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006514066A5 (https=
Inventor
ヴェンカタ・パレ
ジェフ・ザブロッキ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Palo Alto Inc
Original Assignee
CV Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CV Therapeutics Inc filed Critical CV Therapeutics Inc
Publication of JP2006514066A publication Critical patent/JP2006514066A/ja
Publication of JP2006514066A5 publication Critical patent/JP2006514066A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
JP2004566575A 2003-01-03 2003-12-19 置換ヘテロ環化合物 Pending JP2006514066A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43786003P 2003-01-03 2003-01-03
PCT/US2003/040607 WO2004063180A1 (en) 2003-01-03 2003-12-19 Substituted heterocyclic compounds

Publications (2)

Publication Number Publication Date
JP2006514066A true JP2006514066A (ja) 2006-04-27
JP2006514066A5 JP2006514066A5 (https=) 2006-12-07

Family

ID=32713240

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004566575A Pending JP2006514066A (ja) 2003-01-03 2003-12-19 置換ヘテロ環化合物

Country Status (11)

Country Link
US (3) US7205303B2 (https=)
EP (1) EP1578737B1 (https=)
JP (1) JP2006514066A (https=)
KR (1) KR20050086956A (https=)
AT (1) ATE443058T1 (https=)
AU (1) AU2003303676A1 (https=)
CA (1) CA2512261A1 (https=)
DE (1) DE60329323D1 (https=)
ES (1) ES2329997T3 (https=)
NZ (1) NZ541069A (https=)
WO (1) WO2004063180A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012522733A (ja) * 2009-04-02 2012-09-27 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング オートタキシン阻害剤としての複素環式化合物

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ541069A (en) * 2003-01-03 2008-09-26 Cv Therapeutics Inc Piperazine derivatives as fatty acid oxidation inhibitors
WO2011026241A1 (en) * 2009-09-04 2011-03-10 Zalicus Pharmaceuticals Ltd. Substituted heterocyclic derivatives for the treatment of pain and epilepsy
EP2961403A4 (en) 2013-03-01 2016-11-30 Zalicus Pharmaceuticals Ltd HETEROCYCLIC INHIBITORS OF SODIUM CHANNEL

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS584774A (ja) * 1981-06-23 1983-01-11 ジヤンセン・フア−マシユ−チカ・ナ−ムロ−ゼ・フエンノ−トシヤツプ Ｎ−アリ−ル−ピペラジンアルカンアミド類
JPH03141258A (ja) * 1989-10-25 1991-06-17 Kowa Co 新規なピペラジン誘導体
WO2001062744A2 (en) * 2000-02-22 2001-08-30 Cv Therapeutics, Inc. Substituted piperazine compounds
WO2002032874A2 (en) * 2000-10-17 2002-04-25 The Procter & Gamble Company Substituted heterocyclic compounds for treating multidrug resistance
WO2002032902A1 (en) * 2000-10-20 2002-04-25 Astrazeneca Ab 3,8-diazabicyclo[3.2.1]octanes and their use in the treatment of cardiac arrhythmias
WO2002064576A1 (en) * 2000-10-23 2002-08-22 Cv Therapeutics, Inc. Heteroaryl alkyl piperazine derivatives as fatty acid oxidation inhibitors
CN1381448A (zh) * 2002-05-08 2002-11-27 上海医药工业研究院 芳烷甲酰烷基哌嗪衍生物及其作为脑神经保护剂的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US181352A (en) * 1876-08-22 Improvement in cotton-cleaners
US729499A (en) * 1901-08-12 1903-05-26 John Machaffie Igniter for gas-engines.
US4766125A (en) * 1981-06-23 1988-08-23 Janssen Pharmaceutica N.V. N-aryl-piperazinealkanamides useful for protecting hearts from myocardial injury caused by ischaemia, anoxia or hypoxia
US4558129A (en) 1983-05-18 1985-12-10 Syntex (U.S.A.) Inc. Benzodioxanyl-hydroxyethylene-piperazinyl acetanilides which effect calcium entry and β-blockade
US4567264A (en) * 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
US4588129A (en) * 1983-09-06 1986-05-13 Hudson Oxygen Therapy Sales Company Nebulizer
ATE142497T1 (de) 1989-06-23 1996-09-15 Syntex Inc Ranolazin und verwandte piperazine zur behandlung von geweben, von physischen oder chemischen schäden betroffen
HU209723B (en) 1990-10-31 1994-10-28 Richter Gedeon Vegyeszet Process for producing of piperazine derivatives
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
AU2001238590A1 (en) * 2000-02-22 2001-09-03 Cv Therapeutics, Inc. Substituted piperazine compounds
US6677336B2 (en) * 2000-02-22 2004-01-13 Cv Therapeutics, Inc. Substituted piperazine compounds
US6552023B2 (en) * 2000-02-22 2003-04-22 Cv Therapeutics, Inc. Aralkyl substituted piperazine compounds
US6451798B2 (en) * 2000-02-22 2002-09-17 Cv Therapeutics, Inc. Substituted alkyl piperazine derivatives
AU2001239827A1 (en) * 2000-02-22 2001-09-03 Cv Therapeutics, Inc. Substituted alkylene diamine compounds
WO2003008411A1 (en) 2001-07-19 2003-01-30 Cv Therapeutics, Inc. Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
AU2003300827B2 (en) * 2002-12-05 2009-08-13 Gilead Palo Alto, Inc. Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
NZ541069A (en) * 2003-01-03 2008-09-26 Cv Therapeutics Inc Piperazine derivatives as fatty acid oxidation inhibitors

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS584774A (ja) * 1981-06-23 1983-01-11 ジヤンセン・フア−マシユ−チカ・ナ−ムロ−ゼ・フエンノ−トシヤツプ Ｎ−アリ−ル−ピペラジンアルカンアミド類
JPH03141258A (ja) * 1989-10-25 1991-06-17 Kowa Co 新規なピペラジン誘導体
WO2001062744A2 (en) * 2000-02-22 2001-08-30 Cv Therapeutics, Inc. Substituted piperazine compounds
WO2002032874A2 (en) * 2000-10-17 2002-04-25 The Procter & Gamble Company Substituted heterocyclic compounds for treating multidrug resistance
WO2002032902A1 (en) * 2000-10-20 2002-04-25 Astrazeneca Ab 3,8-diazabicyclo[3.2.1]octanes and their use in the treatment of cardiac arrhythmias
WO2002064576A1 (en) * 2000-10-23 2002-08-22 Cv Therapeutics, Inc. Heteroaryl alkyl piperazine derivatives as fatty acid oxidation inhibitors
CN1381448A (zh) * 2002-05-08 2002-11-27 上海医药工业研究院 芳烷甲酰烷基哌嗪衍生物及其作为脑神经保护剂的应用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012522733A (ja) * 2009-04-02 2012-09-27 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング オートタキシン阻害剤としての複素環式化合物

Also Published As

Publication number Publication date
NZ541069A (en) 2008-09-26
US7205303B2 (en) 2007-04-17
US20080275238A1 (en) 2008-11-06
EP1578737B1 (en) 2009-09-16
DE60329323D1 (de) 2009-10-29
AU2003303676A1 (en) 2004-08-10
EP1578737A1 (en) 2005-09-28
KR20050086956A (ko) 2005-08-30
WO2004063180A1 (en) 2004-07-29
HK1085467A1 (en) 2006-08-25
US20040176356A1 (en) 2004-09-09
ES2329997T3 (es) 2009-12-03
CA2512261A1 (en) 2004-07-29
US7566717B2 (en) 2009-07-28
ATE443058T1 (de) 2009-10-15
US20070155728A1 (en) 2007-07-05

Similar Documents

Publication Publication Date Title
US7566717B2 (en) Substituted heterocyclic compounds
US20080032993A1 (en) Substituted heterocyclic compounds
EP1567525B1 (en) Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
US7026321B2 (en) Substituted heterocyclic compounds
US20070191390A1 (en) Substituted heterocyclic compounds
US7271169B2 (en) Substituted heterocyclic compounds
EP1806346B1 (en) Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
HK1085467B (en) Substituted heterocyclic compounds
HK1111683B (en) Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
HK1083492B (en) Substituted piperazine compounds and their use as fatty acid oxidation inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061020

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061020

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090917

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20100120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100126

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100426

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100507

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100526

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100602

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100831